News - Dermatologicals


Current filters:


Popular Filters

28 to 52 of 117 results

Abraaj sells stake in Opalia Pharma to Recordati


The Dubai-based Abraaj Group, an investor operating in global growth markets, has announced its full…

Abraaj GroupDermatologicalsGastro-intestinalsGenericsMergers & AcquisitionsOpalia PharmaRecordatiRespiratory and PulmonaryRest of the World

Rigel sees clear forward path for fostamatinib but will drop R333


Clinical-stage US drug developer Rigel Pharmaceuticals has announced mixed updates on two of its pipeline…

BiotechnologyDermatologicalsfostamatinibImmunologicalsR333RegulationResearchRigel Pharmaceuticals

High hopes for Cellceutix’ Brilacidin for serious skin infections


US clinical-stage biopharmaceutical company Cellceutix says that it is completing the required documentation…

Antibiotics and Infectious diseasesbrilacidinCellceutixDermatologicalsPharmaceuticalResearch

Pfizer sees mixed top-line results in the first two of five phase III clinical trials of tofacitinib

Pfizer sees mixed top-line results in the first two of five phase III clinical trials of tofacitinib


Pfizer has announced mixed top-line results from two Phase III clinical trials of tofacitinib for the…

DermatologicalsNorth AmericaPfizerPharmaceuticalResearchtofacitinibXeljanz

Novartis reports further progress with its psoriasis candidate secukinumab

Novartis reports further progress with its psoriasis candidate secukinumab


Novartis recently announced results from the head-to-head Phase III FIXTURE study showing secukinumab…


Novartis presents strong new Ph III results with omalizumab in CSU

Novartis presents strong new Ph III results with omalizumab in CSU


Novartis has presented new results from the Phase III ASTERIA I study showing omalizumab was effective…


Astellas’ antifungal study reports positive results


Astellas Pharma has announced positive topline data from the Phase III invasive aspergillosis study (SECURE)…

Asia-PacificAstellas PharmaBasilea PharmaceuticaDermatologicalsisavuconazolePharmaceuticalResearch

Singapore to launch collaborative program into skin research


Singapore is committing close to S$100 million ($79.6 million) to skin research, announced the Skin Research…


LEO Pharma reports positive Phase III data for ingenol mebutate gel in actinic keratosis


Privately-held Danish dermatology specialist LEO Pharma has announced the completion of a Phase III study…

DermatologicalsEuropeingenol mebutate gelLEO PharmaPharmaceuticalResearch

KYTHERA submental fat drug candidate meets all primary endpoints in Ph III


US biotech firm KYTHERA Biopharmaceuticals (Nasdaq: KYTH) saw its stock upgraded to $50 a share from…

ATX-101BayerDermatologicalsKYTHERA BiopharmaceuticalsPharmaceuticalResearch

ICAAC: Positive preliminary results of new luliconazole formulation in onychymycosis trial


Luliconazole, a medication approved in Japan for the treatment of superficial mycosis in a 1% formulation,…

DermatologicalsLuliconazoleNihon NohyakuNorth AmericaPharmaceuticalResearch

Karo Bio gets first milestone in Pfizer collaboration


Under its collaboration with US pharma behemoth Pfizer (NYSE: PFE), Sweden's Karo Bio (STO: KARO) says…

Anti-Arthritics/RheumaticsDermatologicalsFinancialKaro BioLicensingNeurologicalPfizerPharmaceuticalResearch

Rigel Pharma to focus on three leading clinical programs


USA-based Rigel Pharmaceuticals (Nasdaq: RIGL) today announced its plans to focus the company's resources…

DermatologicalsfostamatinibManagementOphthalmicsPharmaceuticalR333R348ResearchRigel Pharmaceuticals

Onglyza meets primary safety endpoint in SAVOR CV outcomes trial


Anglo-Swedish drug major AstraZeneca (LSE: AZN) and US partner Bristol-Myers Squibb (NYSE: MBY) today…

AstraZenecaBristol-Myers SquibbCardio-vascularDermatologicalsOnglyzaPharmaceuticalResearch

NovaBiotics enters co-development agreement for Novexatin


Scotland-headquartered clinical-stage biotech firm NovaBiotics has entered into an exclusive agreement…

BiotechnologyDermatologicalsLicensingNovaBioticsNovexatinTaro Pharmaceuticals

Galderma drug is first FDA-approved facial erythema of rosacea treatment


Switzerland-headquartered Galderma Laboratories says that the US Food and Drug Administration has approved…

brimonidineDermatologicalsGaldermaMirvasoNorth AmericaPharmaceuticalRegulation

Actelion bid for Ceptaris looks secured as FDA approves Valchlor


Privately-held USA-based Ceptaris Therapeutics revealed yesterday (August 26) that the US Food and Drug…

ActelionBiotechnologyCeptaris TherapeuticsDermatologicalsMergers & AcquisitionsNorth AmericaRegulationValchlor

First in class novel biologic for psoriasis launched in India


Bangalore, India-based Biocon (BSE: 532523), Asia's premier biotechnology company, has launched its 'first…

ALZUMAbAsia-PacificBioconBiotechnologyDermatologicalsitolizumabMarkets & Marketing

Mayne Pharma signs up deals to market Subacap in Europe


Australian drugmaker Mayne Pharma (ASX: MYX) says it has signed two marketing and distribution agreements…

DermatologicalsEuropeGlenmark PharmaceuticalsIsdinitraconazoleLicensingMarkets & MarketingMayne PharmaPharmaceuticalSubacap

EMA suspends use of oral ketoconazole because of liver injury risk


The European Medicines Agency's Committee on Medicinal Products for Human Use (CHMP) has recommended…


Galen in upfront $4.5million deal with Novo Research for US rights for Synera pain relief patch


Canada's Nuvo Research (TSX: NRI) today (July 11) announced that its wholly owned subsidiary, ZARS Pharma,…

DermatologicalsGalen USLicensingNorth AmericaNuvo ResearchPharmaceuticalSyneraZARS Pharma

Novartis' secukinumab demonstrates superiority to rival Enbrel in psoriasis study


Swiss drug major Novartis (NOVN: VX) has announced results from a Phase III psoriasis study which showed…

AbbVieAmgenDermatologicalsEnbrelHumiraJanssen BiotechNovartisPharmaceuticalsecukinumabStelara Injectiontofacitinib

Swedish Pergamum reports positive preliminary efficacy results of LL-37 in chronic leg ulcers


Pergamum, a portfolio company of Sweden-based investment company Karolinska Development, says that the…

BiotechnologyDermatologicalsKarolinska DevelopmentResearch

28 to 52 of 117 results

Back to top